Edition:
United States

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.31USD
12 Dec 2017
Change (% chg)

$-0.07 (-5.07%)
Prev Close
$1.38
Open
$1.39
Day's High
$1.39
Day's Low
$1.31
Volume
479,594
Avg. Vol
659,828
52-wk High
$1.77
52-wk Low
$0.73

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $410.84
Shares Outstanding(Mil.): 313.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Novavax reports Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Novavax Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Novavax reports Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Aug 08 2017

BRIEF-Novavax announces positive topline data from phase 2 trial and provides path forward for RSV F vaccine programs

* Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs Source text for Eikon: Further company coverage:

Jul 24 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.00 -0.55
Merck & Co., Inc. (MRK.N) $57.07 +0.73
Sanofi SA (SASY.PA) €75.17 +0.14
GlaxoSmithKline plc (GSK.L) 1,315.50 +1.00
AstraZeneca plc (AZN.L) 4,932.50 -2.50

Earnings vs. Estimates